Sana Biotechnology Quarterly Balance Sheets Chart
Quarterly
|
Annual
Sana Biotechnology Quarterly Balance Sheets Table
Quarterly
|
Annual
| Unit: USD | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | 2023-03-31 | 2022-12-31 | 2022-09-30 | 2022-06-30 | 2022-03-31 | 2021-12-31 | 2021-09-30 | 2021-06-30 | 2021-03-31 | 2020-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| assets | |||||||||||||||||||
| current assets: | |||||||||||||||||||
| cash and cash equivalents | 71,271,000 | 96,131,000 | 127,566,000 | 126,996,000 | 134,958,000 | 177,054,000 | 133,517,000 | 168,448,000 | 173,787,000 | 160,456,000 | 176,765,000 | 163,343,000 | 194,659,000 | 188,517,000 | 253,029,000 | 433,670,000 | 675,140,000 | 750,687,000 | 124,806,000 |
| marketable securities | 1,403,000 | 8,570,000 | 24,931,000 | 72,011,000 | 116,685,000 | 134,028,000 | 71,678,000 | 100,122,000 | 152,128,000 | 188,850,000 | 247,198,000 | 322,407,000 | 290,143,000 | 323,861,000 | 297,967,000 | 170,041,000 | 177,696,000 | 209,550,000 | 253,458,000 |
| restricted cash | 4,195,000 | 4,195,000 | 3,832,000 | 3,832,000 | 3,832,000 | 3,832,000 | 3,832,000 | 3,832,000 | 6,100,000 | 6,100,000 | 6,100,000 | 6,100,000 | 10,508,000 | 8,819,000 | 8,819,000 | 8,819,000 | 2,143,000 | 2,143,000 | 2,143,000 |
| prepaid expenses and other current assets | 5,633,000 | 3,835,000 | 4,479,000 | 7,310,000 | 7,978,000 | 6,349,000 | 4,488,000 | 7,120,000 | 6,606,000 | 14,502,000 | 14,374,000 | 8,400,000 | 9,612,000 | 10,842,000 | 7,105,000 | 9,134,000 | 7,504,000 | 7,237,000 | 6,203,000 |
| total current assets | 82,502,000 | 112,731,000 | 160,808,000 | 210,149,000 | 263,453,000 | 321,263,000 | 213,515,000 | 279,522,000 | 338,621,000 | 369,908,000 | 444,437,000 | 500,250,000 | 494,414,000 | 523,220,000 | 558,101,000 | 612,845,000 | 860,340,000 | 967,474,000 | 384,467,000 |
| property and equipment | 33,081,000 | 73,687,000 | 77,308,000 | 82,826,000 | 85,909,000 | 81,649,000 | 70,689,000 | 68,369,000 | 62,654,000 | 64,260,000 | 66,917,000 | 67,349,000 | 67,846,000 | 68,693,000 | 65,464,000 | 63,445,000 | 58,670,000 | 50,986,000 | 46,775,000 |
| operating lease right-of-use assets | 43,021,000 | 54,837,000 | 57,961,000 | 61,040,000 | 63,154,000 | 71,565,000 | 74,903,000 | 77,235,000 | 94,715,000 | 98,116,000 | 92,486,000 | 95,733,000 | 98,910,000 | 97,145,000 | 96,320,000 | 84,828,000 | 60,330,000 | 61,770,000 | 63,168,000 |
| intangible asset | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 | 59,195,000 |
| goodwill | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 | 140,627,000 |
| other non-current assets | 3,219,000 | 4,393,000 | 5,121,000 | 5,555,000 | 6,329,000 | 7,078,000 | 6,370,000 | 6,492,000 | 6,927,000 | 4,589,000 | 4,599,000 | 4,717,000 | 4,825,000 | 4,900,000 | 5,000,000 | 591,000 | 598,000 | 644,000 | 190,000 |
| total assets | 361,645,000 | 445,470,000 | 501,020,000 | 559,392,000 | 618,667,000 | 681,377,000 | 565,299,000 | 631,440,000 | 707,147,000 | 746,928,000 | 822,720,000 | 898,102,000 | 971,089,000 | 1,047,613,000 | 1,129,407,000 | 1,232,751,000 | 1,259,837,000 | 1,304,466,000 | 730,296,000 |
| liabilities and stockholders' equity | |||||||||||||||||||
| current liabilities: | |||||||||||||||||||
| accounts payable | 2,270,000 | 989,000 | 5,210,000 | 2,991,000 | 3,817,000 | 6,095,000 | 4,108,000 | 9,928,000 | 3,089,000 | 2,334,000 | 2,857,000 | 3,993,000 | 3,079,000 | 4,765,000 | 2,219,000 | 3,947,000 | 3,704,000 | 4,258,000 | 2,253,000 |
| accrued compensation | 9,411,000 | 9,354,000 | 14,449,000 | 18,050,000 | 15,581,000 | 13,965,000 | 23,722,000 | 24,286,000 | 19,669,000 | 17,029,000 | 26,362,000 | 24,500,000 | 17,991,000 | 16,889,000 | 21,131,000 | 20,218,000 | 15,294,000 | 10,811,000 | 16,020,000 |
| accrued expenses and other current liabilities | 7,931,000 | 9,810,000 | 13,240,000 | 15,362,000 | 21,293,000 | 19,674,000 | 23,462,000 | 18,940,000 | 18,040,000 | 13,298,000 | 14,547,000 | 14,970,000 | 13,985,000 | 11,321,000 | 10,344,000 | 12,884,000 | 12,830,000 | 11,171,000 | 9,466,000 |
| operating lease liabilities | 13,832,000 | 13,003,000 | 12,534,000 | 10,601,000 | 9,998,000 | 13,167,000 | 13,195,000 | 13,490,000 | 12,890,000 | 12,892,000 | 12,393,000 | 11,921,000 | 10,667,000 | 9,635,000 | 9,159,000 | 6,502,000 | 6,004,000 | 3,910,000 | 3,712,000 |
| total current liabilities | 33,444,000 | 33,156,000 | 45,433,000 | 47,004,000 | 50,689,000 | 52,901,000 | 64,487,000 | 66,644,000 | 112,105,000 | 102,777,000 | 111,504,000 | 114,813,000 | 97,108,000 | 93,510,000 | 99,235,000 | 92,010,000 | 42,832,000 | 35,150,000 | 31,451,000 |
| operating lease liabilities, net of current portion | 71,660,000 | 78,311,000 | 81,663,000 | 85,483,000 | 88,559,000 | 92,922,000 | 90,901,000 | 83,374,000 | 100,245,000 | 101,607,000 | 95,860,000 | 99,859,000 | 102,960,000 | 102,518,000 | 101,784,000 | 92,403,000 | 66,149,000 | 66,349,000 | 68,197,000 |
| contingent consideration | 117,132,000 | 110,832,000 | 108,968,000 | 111,856,000 | 111,621,000 | 114,990,000 | 58,417,000 | 57,224,000 | 55,345,000 | 59,429,000 | 51,386,000 | 50,900,000 | 51,382,000 | 43,459,000 | 140,457,000 | 133,294,000 | 121,901,000 | ||
| success payment liabilities | 8,611,000 | 4,649,000 | 4,556,000 | 15,115,000 | 20,847,000 | 45,422,000 | 12,799,000 | 12,414,000 | 5,000,000 | 5,000,000 | 5,000,000 | 5,000,000 | 76,494,000 | ||||||
| other non-current liabilities | 8,242,000 | 9,443,000 | 9,896,000 | 7,456,000 | 7,302,000 | 539,000 | 539,000 | 539,000 | 540,000 | ||||||||||
| total liabilities | 239,089,000 | 236,391,000 | 250,516,000 | 266,914,000 | 279,018,000 | 306,235,000 | 277,793,000 | 265,588,000 | 352,118,000 | 318,666,000 | 323,405,000 | 332,083,000 | 331,584,000 | 345,958,000 | 400,905,000 | 402,666,000 | 353,940,000 | 422,483,000 | 298,583,000 |
| commitments and contingencies | |||||||||||||||||||
| stockholders' equity: | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of june 30, 2025 and december 31, 2024 | |||||||||||||||||||
| common stock | 23,000 | 23,000 | 22,000 | 22,000 | 22,000 | 22,000 | 20,000 | 20,000 | 20,000 | 19,000 | 19,000 | 19,000 | 19,000 | 19,000 | 18,000 | 18,000 | 18,000 | 18,000 | 2,000 |
| additional paid-in capital | 1,870,572,000 | 1,863,295,000 | 1,855,318,000 | 1,848,183,000 | 1,835,503,000 | 1,820,701,000 | 1,625,637,000 | 1,616,008,000 | 1,606,832,000 | 1,567,341,000 | 1,558,459,000 | 1,546,807,000 | 1,535,106,000 | 1,523,616,000 | 1,515,210,000 | 1,504,778,000 | 1,497,232,000 | 1,491,958,000 | 8,216,000 |
| accumulated other comprehensive income | 14,000 | 54,000 | -1,366,000 | -82,000 | 13,000 | 56,000 | 30,000 | ||||||||||||
| accumulated deficit | -1,748,039,000 | -1,654,239,000 | -1,604,850,000 | -1,555,781,000 | -1,495,857,000 | -1,445,566,000 | -1,338,091,000 | -1,249,974,000 | -1,250,958,000 | -1,136,959,000 | -1,054,836,000 | -974,393,000 | -889,273,000 | -816,808,000 | -785,360,000 | -674,629,000 | -591,366,000 | -610,049,000 | -429,432,000 |
| total stockholders' equity | 122,556,000 | 209,079,000 | 250,504,000 | 292,478,000 | 339,649,000 | 375,142,000 | 287,506,000 | 365,852,000 | 355,029,000 | 428,262,000 | 499,315,000 | 566,019,000 | 639,505,000 | 701,655,000 | 728,502,000 | 830,085,000 | 905,897,000 | 881,983,000 | |
| total liabilities and stockholders' equity | 361,645,000 | 445,470,000 | 501,020,000 | 559,392,000 | 618,667,000 | 681,377,000 | 565,299,000 | 631,440,000 | 707,147,000 | 746,928,000 | 822,720,000 | 898,102,000 | 971,089,000 | 1,047,613,000 | |||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of march 31, 2025 and december 31, 2024 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of december 31, 2024 and december 31, 2023 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of september 30, 2024 and december 31, 2023 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of june 30, 2024 and december 31, 2023 | |||||||||||||||||||
| accumulated other comprehensive loss | -19,000 | -15,000 | -60,000 | -202,000 | -865,000 | -2,139,000 | -4,327,000 | -6,414,000 | -6,347,000 | -5,172,000 | |||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of march 31, 2024 and december 31, 2023 | |||||||||||||||||||
| long-term marketable securities | 5,825,000 | 10,051,000 | 25,823,000 | 94,764,000 | 145,014,000 | 195,881,000 | 262,401,000 | 77,934,000 | 21,627,000 | 33,731,000 | |||||||||
| long-term restricted cash | 4,408,000 | 4,408,000 | 4,408,000 | 4,408,000 | |||||||||||||||
| contingent consideration, net of current portion | 109,606,000 | 103,156,000 | 103,317,000 | 98,615,000 | 95,034,000 | 81,701,000 | 97,999,000 | 102,315,000 | 102,361,000 | 88,522,000 | |||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of december 31, 2023 and december 31, 2022 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of september 30, 2023 and december 31, 2022 | |||||||||||||||||||
| success payment liabilities, net of current portion | 36,451,000 | 15,667,000 | 21,007,000 | 35,710,000 | 33,517,000 | 47,615,000 | 97,525,000 | 129,192,000 | 103,963,000 | 187,151,000 | |||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of june 30, 2023 and december 31, 2022 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of march 31, 2023 and december 31, 2022 | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of december 31, 2022 and 2021, respectively | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of september 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of june 30, 2022 and december 31, 2021, respectively | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 shares authorized; zero shares issued and outstanding as of march 31, 2022 and december 31, 2021, respectively | |||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders' equity | |||||||||||||||||||
| convertible preferred stock | 852,897,000 | ||||||||||||||||||
| stockholders' equity | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 and zero shares authorized as of december 31, 2021 and 2020, respectively; zero shares issued and outstanding as of december 31, 2021 and 2020 | |||||||||||||||||||
| total liabilities, convertible preferred stock, and stockholders' equity | 1,129,407,000 | 1,232,751,000 | 1,259,837,000 | 1,304,466,000 | |||||||||||||||
| preferred stock, 0.0001 par value; 50,000 and zero shares authorized as of september 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding as of september 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 and zero shares authorized as of june 30, 2021 and december 31, 2020, respectively; zero shares issued and outstanding as of june 30, 2021 and december 31, 2020, respectively | |||||||||||||||||||
| preferred stock, 0.0001 par value; 50,000 and zero shares authorized as of march 31, 2021 and december 31, 2020, respectively; zero shares issued and outstanding as of march 31, 2021 and december 31, 2020, respectively | |||||||||||||||||||
| liabilities, convertible preferred stock, and stockholders’ deficit | |||||||||||||||||||
| stockholders’ deficit: | |||||||||||||||||||
| total stockholders’ deficit | -421,184,000 | ||||||||||||||||||
| total liabilities, convertible preferred stock, and stockholders deficit | 730,296,000 | ||||||||||||||||||
| operating expenses: | |||||||||||||||||||
| research and development | 257,879,000 | ||||||||||||||||||
| general and administrative | 28,270,000 | ||||||||||||||||||
| total operating expenses | 286,149,000 | ||||||||||||||||||
| income from operations | -286,149,000 | ||||||||||||||||||
| interest income | 747,000 | ||||||||||||||||||
| other income | 97,000 | ||||||||||||||||||
| income before income taxes | -285,305,000 | ||||||||||||||||||
| benefit from income taxes | |||||||||||||||||||
| net income | -285,305,000 | ||||||||||||||||||
| net income per share | -21,920 | ||||||||||||||||||
| weighted-average shares outstanding, basic and diluted | 13,014,000 |
We provide you with 20 years of balance sheets for Sana Biotechnology stock, allowing you to gain comprehensive visibility into the fundamentals of the company. Our detailed breakdowns include key financial metrics such as asset and liabilities, payables and receivables, long debts and short debts, cash and inventories, expenses and profits. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of Sana Biotechnology. Explore the full financial landscape of Sana Biotechnology stock with our expertly curated balance sheets.
The information provided in this report about Sana Biotechnology stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.